Massive RSV vaccine study uses real-world data to see if shots prevent severe illness
NCT ID NCT07673081
First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time
Summary
This study looks at the real-world effectiveness of the RSV vaccine Abrysvo in adults. Researchers will analyze health records from over 290,000 people to compare those who got the vaccine with those who did not. The goal is to see if the vaccine reduces hospitalizations and other serious outcomes from RSV-related respiratory infections.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RSVpreF (Abrysvo) vaccine
- What this could lead to
- If effective, this could confirm that the RSV vaccine helps prevent serious lung infections and hospital stays in older adults.
- What could go wrong
- This is an observational study, not a controlled trial, so results may be influenced by differences between vaccinated and unvaccinated groups.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUS (RSV) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One shot, two viruses? new mRNA vaccine targets RSV and hMPV
- New mRNA vaccine aims to shield against RSV
- New RSV vaccine aims to shield adults from severe respiratory infection
- Scientists test RSV vaccine to boost immune memory
- New study tracks RSV in pregnant women and their babies
- One shot to stop RSV: landmark trial for indigenous kids